Home > Insider Trading > Filing (0001181431-11-016805)

Filing Details

Accession Number:: 0001181431-11-016805
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2011-03-09 12:00:00
Reporting Period:: 2010-12-07

Filing Date:: 2011-03-09
Accepted Time:: 2011-03-09 16:24:58
Original Submission Date:: 2010-12-09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1325879	Aveo Pharmaceuticals Inc	AVEO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1486373	G. Douglas Cole	C/O Aveo Pharmaceuticals, Inc. 75 Sidney Street Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2010-12-07	359	$14.93	44,988	No	4	S	Indirect	by AGTC Advisors Fund, L.P.
Common Stock	Disposition	2010-12-07	5,935	$14.93	744,343	No	4	S	Indirect	by Applied Genomic Technology Capital Fund, L.P.
Common Stock	Disposition	2010-12-08	1,562	$14.93	43,426	No	4	S	Indirect	by AGTC Advisors Fund, L.P.
Common Stock	Disposition	2010-12-08	25,838	$14.93	7,185,058	No	4	S	Indirect	by Applied Genomic Technology Capital Fund, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	by AGTC Advisors Fund, L.P.
No	4	S	Indirect	by Applied Genomic Technology Capital Fund, L.P.
No	4	S	Indirect	by AGTC Advisors Fund, L.P.
No	4	S	Indirect	by Applied Genomic Technology Capital Fund, L.P.

Footnotes

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by AGTC Advisors Fund, L.P. on November 9, 2010.
The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.73 to $15.03, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
The number of shares were incorrectly reported on the reporting person's From 4 filed on December 9, 2010, and on subsequent Forms 4 filed by the reporting person.
Held by AGTC Advisors Fund, L.P.; NewcoGen Group, Inc. ("NewcoGen Inc.") is the general partner of AGTC Partners, L.P., which is the general partner of AGTC Advisors Fund, L.P. NewcoGen Inc. is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship Inc."). Noubar B. Ayefan Ph.D. and Edwin M. Kania, Jr. are the directors of Flagship Inc. and may be deemed to have beneficial ownership with respect to all shares held by AGTC Advisors Fund, L.P. The reporting person disclaims beneficial owenrship over shares held by AGTC Advisors Fund, L.P.
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Applied Genomic Technology Capital Fund, L.P. on November 9, 2010.
Held by Applied Genomic Technology Capital Fund, L.P.; NewcoGen, Inc. is the general partner of AGTC Partners, L.P., which is the general partner of Applied Genomic Technology Capital Fund, L.P. NewcoGen Inc. is a wholly-owned subsidiary of Flagship Inc. Noubar B. Afeyan Ph.D. and Edwin M. Kania, Jr. are the directors of Flagship Inc. and they may be deemed to have beneficial ownership with respect to all shares held by Applied Genomic Technology Capital Fund, L.P. The reporting person disclaims beneficial ownership over shares held by Applied Genomic Technology Capital Fund, L.P.
The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.72 to $15.02, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.